Core Insights - Theriva Biologics is advancing its VCN-X discovery program with VCN-12, which shows a novel mechanism of action that may significantly enhance antitumor effects [1][2] - The company will present preclinical data on VCN-01's intracranial administration for brain tumor treatment at the upcoming ESGCT Congress [1][3] Company Overview - Theriva Biologics is a clinical-stage company focused on developing therapeutics for cancer and related diseases, addressing areas with high unmet medical needs [4] - The company's lead candidates include VCN-01, an oncolytic adenovirus designed to selectively replicate within tumor cells and degrade tumor stroma, and SYN-004 and SYN-020, which target gastrointestinal health and systemic diseases [4][5] Product Details - VCN-12 is derived from VCN-01 and is engineered with additional transgenes to improve tumor cell lysis, enhance stroma degradation, and boost the antitumor immune response [2][5] - VCN-01 has been administered to 142 patients across various cancer types, demonstrating its potential in combination with other therapies [6]